Rochester Clinical Research is proud to have helped approve the Merck Ebola Vaccination Clinical Trials. During the study, it was 100% successful leading to the approval of using it in the Democratic Republic of Congo where a deadly outbreak has occured resulting in 50 cases and 25 deaths this spring. Over 7,500 doses have been sent to the DRC which is expected to be extremely helpful in the outbreak. Emergency teams and the World Health Organization (WHO) are administering the vaccine which were donated by Merck to many individuals in the DRC, especially it’s capital.
A big thank you to all of our volunteers who helped make this study vaccine available to people in the Democrative Republic of Congo. It could not have happened without you.